SynthesisReviews in cardiovascular medicine2023
Omega-3 Polyunsaturated Fatty Acids Supplements and Cardiovascular Disease Outcome: A Systematic Review and Meta-Analysis on Randomized Controlled Trials.
Synthesis in Reviews in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial.Nature aging · 2025Trial
- Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities.Biomedicines · 2026Review
- Regulation of inflammation by omega-3 and omega-6 fatty acids: a meta-analysis of randomized trials.Frontiers in nutrition · 2026Article
- Dietary flaxseed: Cardiometabolic benefits and its role in promoting healthy aging.GeroScience · 2025Review
- Inflammation pathways as therapeutic targets in angiotensin II induced atrial fibrillation.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many meta-analyses and randomized controlled trials (RCTs) on the use of Omega-3 supplements for cardiovascular disease (CVD) have come to different outcomes. Besides, previous meta-analyses have missed some key RCTs on this topic. Methods: PubMed, EMBASE, Cochrane Library and Web of Science were manually searched for eligible RCTs on Omega-3 polyunsaturated fatty acids (PUFA) use for CVD. Risk estimates of each relevant outcome were calculated as a hazard ratio (HR) with 95% confidence interval (95% CI) using the random-effects model. Subgroup analysis was conducted according to the main characteristics of the population, sensitivity analysis would be performed if there was significant heterogeneity among analyses on relevant outcomes. Statistical heterogeneity was assessed using chi-square tests and quantified using I-square statistics. Results: Nineteen eligible RCTs incorporating 116,498 populations were included. Omega-3 PUFA supplementation could not significantly improve the outcomes of major adverse cardiovascular events (MACE) (HR: 0.98, 95% CI: 0.91-1.06), myocardial infarction (MI) (HR: 0.86, 95% CI: 0.70-1.05), coronary heart disease (CHD) (HR: 0.90, 95% CI: 0.80-1.01), stroke (HR: 1.00, 95% CI: 0.91-1.10), SCD (sudden cardiac death) (HR: 0.90, 95% CI: 0.80-1.02), all-cause mortality (HR: 0.96, 95% CI: 0.89-1.04), hospitalization (HR: 0.99, 95% CI: 0.81-1.20), hospitalization for all heart disease (HR: 0.91, 95% CI: 0.83-1.00), hospitalization for heart failure (HR: 0.97, 95% CI: 0.91-1.04). Although omega-3 PUFA significantly reduced revascularization (HR: 0.90, 95% CI: 0.81-1.00) and cardiovascular mortality (CV mortality) (HR: 0.91, 95% CI: 0.85-0.97), risk for atrial fibrillation (AF) was also increased (HR: 1.56, 95% CI: 1.27-1.91). Subgroup analysis results kept consistent with the main results. Conclusions: Omega-3 PUFA supplementation could reduce the risk for CV mortality and revascularization, it also increased the AF incidence. No obvious benefits on other CVD outcomes were identified. Overall, potential CVD benefits and harm for AF should be balanced when using omega-3 PUFA for patients or populations at high risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.